These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 20688394)

  • 1. Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome.
    Mavroudi I; Pyrovolaki K; Pavlaki K; Kozana A; Psyllaki M; Kalpadakis C; Pontikoglou C; Papadaki HA
    Leuk Res; 2011 Mar; 35(3):323-8. PubMed ID: 20688394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome.
    Will B; Kawahara M; Luciano JP; Bruns I; Parekh S; Erickson-Miller CL; Aivado MA; Verma A; Steidl U
    Blood; 2009 Oct; 114(18):3899-908. PubMed ID: 19710504
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    D'Alò F; Zangrilli I; Cupelli E; Fianchi L; Criscuolo M; Falconi G; Fabiani E; Pagano L; Hohaus S; De Stefano V
    Platelets; 2021 Apr; 32(3):378-382. PubMed ID: 32268817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The new thrombopoietic agenda: impact on leukemias and MDS.
    Bussel JB
    Best Pract Res Clin Haematol; 2014; 27(3-4):288-92. PubMed ID: 25455280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
    Oliva EN; Alati C; Santini V; Poloni A; Molteni A; Niscola P; Salvi F; Sanpaolo G; Balleari E; Germing U; Fenaux P; Stamatoullas A; Palumbo GA; Salutari P; Impera S; Avanzini P; Cortelezzi A; Liberati AM; Carluccio P; Buccisano F; Voso MT; Mancini S; Kulasekararaj A; Morabito F; Bocchia M; Cufari P; Spiriti MA; Santacaterina I; D'Errigo MG; Bova I; Zini G; Latagliata R
    Lancet Haematol; 2017 Mar; 4(3):e127-e136. PubMed ID: 28162984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone.
    Tamari R; Schinke C; Bhagat T; Roth M; Braunschweig I; Will B; Steidl U; Verma A
    Leuk Lymphoma; 2014 Dec; 55(12):2901-6. PubMed ID: 24650011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
    Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A
    Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eltrombopag in Immune Thrombocytopenia, Aplastic Anemia, and Myelodysplastic Syndrome: From Megakaryopoiesis to Immunomodulation.
    Fattizzo B; Levati G; Cassin R; Barcellini W
    Drugs; 2019 Aug; 79(12):1305-1319. PubMed ID: 31292909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eltrombopag for treatment of thrombocytopenia-associated disorders.
    Merli P; Strocchio L; Vinti L; Palumbo G; Locatelli F
    Expert Opin Pharmacother; 2015; 16(14):2243-56. PubMed ID: 26364898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of eltrombopag for the treatment of thrombocytopenia in hypoplastic myelodysplastic syndrome.
    Gauchan D; Shaaban H; Gedeon D; Maroules M
    Ann Hematol; 2014 Oct; 93(10):1777-8. PubMed ID: 24554304
    [No Abstract]   [Full Text] [Related]  

  • 11. A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.
    Svensson T; Chowdhury O; Garelius H; Lorenz F; Saft L; Jacobsen SE; Hellström-Lindberg E; Cherif H
    Eur J Haematol; 2014 Nov; 93(5):439-45. PubMed ID: 24853277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humanized VB22B minibody for human Mpl stimulates human megakaryopoiesis but does not enhance platelet aggregation.
    Matsuki E; Miyakawa Y; Yamane A; Okamoto S
    Exp Hematol; 2011 Aug; 39(8):829-36. PubMed ID: 21605620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eltrombopag in chronic hepatitis C.
    Mihăilă RG; Cipăian RC
    World J Gastroenterol; 2014 Sep; 20(35):12517-21. PubMed ID: 25253952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist.
    Jenkins JM; Williams D; Deng Y; Uhl J; Kitchen V; Collins D; Erickson-Miller CL
    Blood; 2007 Jun; 109(11):4739-41. PubMed ID: 17327409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist.
    Erickson-Miller CL; Delorme E; Tian SS; Hopson CB; Landis AJ; Valoret EI; Sellers TS; Rosen J; Miller SG; Luengo JI; Duffy KJ; Jenkins JM
    Stem Cells; 2009 Feb; 27(2):424-30. PubMed ID: 19038790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical evaluation of eltrombopag in a PDX model of myelodysplastic syndromes.
    Schmitt N; Jann JC; Altrock E; Flach J; Danner J; Uhlig S; Streuer A; Knaflic A; Riabov V; Xu Q; Mehralivand A; Palme I; Nowak V; Obländer J; Weimer N; Haselmann V; Jawhar A; Darwich A; Weis CA; Marx A; Steiner L; Jawhar M; Metzgeroth G; Boch T; Nolte F; Hofmann WK; Nowak D
    Leukemia; 2022 Jan; 36(1):236-247. PubMed ID: 34172896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real-life study.
    Comont T; Meunier M; Cherait A; Santana C; Cluzeau T; Slama B; Laribi K; Giraud JT; Dimicoli S; Berceanu A; Le Clech L; Cony-Makhoul P; Gruson B; Torregrosa J; Sanhes L; Jachiet V; Azerad MA; Al Jijakli A; Gyan E; Gaudin C; Broner J; Guerveno C; Guillaume T; Ades PL; Beyne-Rauzy O; Fenaux P;
    Br J Haematol; 2021 Jul; 194(2):336-343. PubMed ID: 34151423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders.
    Pathak S; Roth M; Verma A; Steidl U
    Expert Opin Drug Metab Toxicol; 2013 Dec; 9(12):1667-75. PubMed ID: 24215532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombopoietic agents.
    Stasi R; Bosworth J; Rhodes E; Shannon MS; Willis F; Gordon-Smith EC
    Blood Rev; 2010; 24(4-5):179-90. PubMed ID: 20493600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of severe thrombocytopenia with the use of thrombopoeitin receptor agonist eltrombopag in a patient with chronic myelomonocytic leukemia.
    Modi Y; Shaaban H; Gauchan D; Maroules M
    J Oncol Pharm Pract; 2015 Feb; 21(1):74-5. PubMed ID: 25063763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.